INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 215 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.35 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,347 | -97.6% | 6,034 | -94.9% | 0.00% | -100.0% |
| Q1 2023 | $97,705 | -76.8% | 119,153 | -55.8% | 0.00% | -50.0% |
| Q4 2022 | $420,902 | -43.0% | 269,809 | -37.0% | 0.00% | -50.0% |
| Q3 2022 | $738,000 | +132.1% | 427,961 | +572.0% | 0.00% | +33.3% |
| Q4 2021 | $318,000 | +1666.7% | 63,685 | +2447.4% | 0.00% | – |
| Q3 2021 | $18,000 | -93.4% | 2,500 | -91.5% | 0.00% | -100.0% |
| Q1 2021 | $272,000 | +277.8% | 29,316 | +260.5% | 0.00% | +200.0% |
| Q4 2020 | $72,000 | -85.8% | 8,132 | -81.4% | 0.00% | -85.7% |
| Q3 2020 | $506,000 | +1134.1% | 43,616 | +249.0% | 0.01% | +600.0% |
| Q4 2019 | $41,000 | -57.3% | 12,499 | -61.9% | 0.00% | -50.0% |
| Q2 2019 | $96,000 | +88.2% | 32,802 | +140.2% | 0.00% | 0.0% |
| Q1 2019 | $51,000 | -32.9% | 13,658 | -27.9% | 0.00% | -50.0% |
| Q4 2018 | $76,000 | -20.8% | 18,941 | -6.9% | 0.00% | -33.3% |
| Q1 2018 | $96,000 | -58.6% | 20,336 | -49.2% | 0.01% | -50.0% |
| Q3 2015 | $232,000 | – | 40,059 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| GSA CAPITAL PARTNERS LLP | 100,274 | $82 | 0.01% |